APPLICATIONS OF LONG-READ SEQUENCING IN CLINICAL GENOMICS
Dr Ira Deveson,
Laboratory Head
Genomic Technologies Research Lab,
Garvan Institute of Medical Research,
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | October 2026
Dr Ira Deveson is a mid-career researcher and Snow Fellow. He has expertise in clinical genomics, biotechnology development and bioinformatics, with his lab focusing on applications of long-read sequencing in clinical genomics. His work spans from computational methods development and software/hardware engineering, to large-scale genomic analysis of diverse cohorts in health and disease.
Dr Ira Deveson graduated with a Bachelor of Philosophy from the Australian National University in 2012. He completed a PhD at the Garvan Institute of Medical Research from 2014-2017, supervised by Prof John Mattick and Dr Tim Mercer. Dr Deveson’s PhD focused on genome/transcriptome research and bioinformatics, and earned him recognition with the JD Catcheside prize from the Genetics Society of Australasia.
Dr Deveson was appointed as Head of Garvan’s Genomic Technologies Lab in 2020 and has since been awarded multiple significant NHMRC and MRFF grants to support his work on long-read sequencing technology development. He currently holds an NHMRC Investigator Grant (L1) and a prestigious Snow Medical Fellowship. His research has been published in leading science journals including Nature, Nature Biotechnology and Nature Methods. In addition to his research role, Dr Deveson leads the Long-read Sequencing Hub within Garvan’s Genomics Platform.
Source: Supplied
You Might also like
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Next Generation Condom Contraception, Dr David Shepherd
Dr David Shepherd is a Lead Production Engineer and Materials Specialist at Eudaemon Technologies. His journey began at the University of Wollongong, where he pursued advanced studies and eventually obtained a PhD under the guidance of a distinguished professor. His research initially focused on actuating materials and artificial muscles, particularly centred around hydrogel materials. These early explorations have seamlessly evolved into his current focus on utilising hydrogels in the realm of sexual reproductive health, with a specific emphasis on developing innovative hydrogel condoms.
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
https://orcid.org/0000-0003-3861-0472